Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - risperidone, quantity: 0.5 mg - tablet, film coated - excipient ingredients: titanium dioxide; stearic acid; microcrystalline cellulose; iron oxide red; hypromellose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; lactose monohydrate - treatment of schizophrenia and related psychoses.,short-term treatment of acute mania associated with bipolar i disorder.,treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; iron oxide red - ? risperidone tablets are indicated for the treatment of schizophrenia and related psychoses. ? risperidone tablets are indicated for the short-term treatment of acute mania associated with bipolar 1 disorder (see section 4.2 dose and method of administration ? bipolar mania)). ? risperidone tablets are also indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see section 4.2 dose and method of administration: behavioural disturbances in dementia) ? risperidone tablets are indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent. (see section 5.1 pharmacodynamic properties ? clinical trials for maintenance data). ? risperidone tablets are indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see section 5.1 pharmacodynamic properties ? clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; iron oxide yellow - ? risperidone tablets are indicated for the treatment of schizophrenia and related psychoses. ? risperidone tablets are indicated for the short-term treatment of acute mania associated with bipolar 1 disorder (see section 4.2 dose and method of administration ? bipolar mania)). ? risperidone tablets are also indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see section 4.2 dose and method of administration: behavioural disturbances in dementia) ? risperidone tablets are indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent. (see section 5.1 pharmacodynamic properties ? clinical trials for maintenance data). ? risperidone tablets are indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see section 5.1 pharmacodynamic properties ? clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol; sunset yellow fcf aluminium lake - ? risperidone tablets are indicated for the treatment of schizophrenia and related psychoses. ? risperidone tablets are indicated for the short-term treatment of acute mania associated with bipolar 1 disorder (see section 4.2 dose and method of administration ? bipolar mania)). ? risperidone tablets are also indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see section 4.2 dose and method of administration: behavioural disturbances in dementia) ? risperidone tablets are indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent. (see section 5.1 pharmacodynamic properties ? clinical trials for maintenance data). ? risperidone tablets are indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see section 5.1 pharmacodynamic properties ? clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; lactose monohydrate; sodium lauryl sulfate; purified talc; magnesium stearate; titanium dioxide; hypromellose; propylene glycol - ? risperidone tablets are indicated for the treatment of schizophrenia and related psychoses. ? risperidone tablets are indicated for the short-term treatment of acute mania associated with bipolar 1 disorder (see section 4.2 dose and method of administration ? bipolar mania)). ? risperidone tablets are also indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. (see section 4.2 dose and method of administration: behavioural disturbances in dementia) ? risperidone tablets are indicated in the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent. (see section 5.1 pharmacodynamic properties ? clinical trials for maintenance data). ? risperidone tablets are indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see section 5.1 pharmacodynamic properties ? clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; indigo carmine aluminium lake; lactose monohydrate; quinoline yellow; pregelatinised maize starch; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses.,short-term treatment of acute mania associated with bipolar i disorder.,treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: quinoline yellow; lactose monohydrate; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses.,short-term treatment of acute mania associated with bipolar i disorder.,treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; iron oxide yellow; iron oxide red; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses.,short-term treatment of acute mania associated with bipolar i disorder.,treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - treatment of schizophrenia and related psychoses.,short-term treatment of acute mania associated with bipolar i disorder.,treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - risperidone, quantity: 6 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; maize starch; lactose monohydrate; magnesium stearate; colloidal anhydrous silica; quinoline yellow; hypromellose; titanium dioxide; macrogol 400 - risperidone is indicated for the treatment of schizophrenia and related psychoses. risperidone is indicated for the treatment of behavioural disturbances in dementia. risperidone is indicated for the treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with sub average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.